2.3.1.22	analysis	development of a MGAT enzymatic assay of human intestinal microsomes using a high-throughput mass spectrometry-based detection system	758472	
2.3.1.22	analysis	development of LC/ESI/MS/MS-based fat absorption assay using 1-oleoyl-glycerol-d5 and U13C-triglyceride to assess the ability of MGAT2 inhibitors to inhibit fat absorption in CD1 mice by a meal tolerance test	755776	
2.3.1.22	drug development	[acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome	735755	
2.3.1.22	medicine	enzyme deficiency protects mice from metabolic disorders (obesity, glucose intolerance, hypercholesterolemia, and fatty liver) despite high-fat diet, caloric intake is normal and dietary fat is absorbed fully but entry into the circulation is reduced, enzyme may be useful target to treat obesity and other metabolic diseases associated with excessive fat intake	705856	
2.3.1.22	medicine	enzyme expression is not affected during diabetes, while total intestinal activity is significantly increased. Up-regulation of both enzyme expression and activity in animals fed with high fat diet	659335	
2.3.1.22	medicine	expression of MGAT1 is robustly induced during adipocyte differentiation and its expression is suppressed in fat of genetically-obese mice	757377	
2.3.1.22	medicine	expression of MGAT1 is robustly induced during adipocyte differentiation and its expression is suppressed in metabolically abnormal obese human subjects	757377	
2.3.1.22	medicine	selective inhibition may provide a novel treatment for obesity and its related metabolic complications, defective triacylglycerol synthesis and storage can lead to severe insulin resistance, excess triacylglycerol accumulation leads to obesity, ectopic storage in nonadipose tissues such as liver and skeletal muscle is associated with insulin resistance	701625	
2.3.1.22	pharmacology	[acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome	735755